Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc (NYSE: MRK) reported its financial results for the third quarter on Thursday that beat Wall Street estimates. Shares of the pharmaceutical company were up 2.0% in premarket trading on upbeat guidance for the full year.

Merck CEO on upbeat guidance: ‘our COVID pill will make a meaningful difference'

"We're on pace to have 10 million courses ready before the end of this year, and more than double that next year," Merck CEO Robert Davis told CNBC on Thursday.

Merck ready to quickly deploy Covid antiviral pill if it gets regulatory approval, CEO says

Shares of Merck & Co. Inc. MRK, +5.73% rose 1.0% in premarket trading Thursday, after the drug maker and animal health company reported third-quarter profit and revenue that rose above expectations and provided and upbeat full-year outlook. Net income rose to $4.57 billion, or $1.80 a share, from $2.94 billion, or $1.16 a share, in the year-ago period.

Merck stock gains after profit and revenue rise above expectations, and upbeat full-year outlook

U.S. drugmaker Merck & Co Inc reported a 55% rise in third-quarter profit on Thursday, helped by strong sales of blockbuster cancer drug Keytruda and recovery in demand for its non-COVID-19 vaccines, as well as lower expenses.

Merck profit jumps on strong vaccine, cancer drug sales

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Third-Quarter 2021 Financial Results

Merck Announces Third-Quarter 2021 Financial Results

AbbVie

Gilead Sciences

As volatility increases, investors tend to shift their focus to strong dividend payers to help them weather the storm.

Cure Your Income Deficiency With These 3 Healthcare Dividend Gems

Amgen

Fidelity MSCI Health Care ETF

iShares U.S. Healthcare ETF

Johnson & Johnson

Eli Lilly

Pfizer

UnitedHealth Group

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.

Healthcare ETFs in Focus as Q3 Earnings Unfold

Merck & Co. (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Merck & Co. (MRK) Ahead of Earnings?

These two pharma giants are among the safest plays in the market right now.

2 Top Dividend Stocks That Can Safeguard Your Portfolio Against a Market Crash

Merck & Co Inc (NYSE: MRK) has signed a licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) to allow more companies to manufacture generic versions of its experimental oral antiviral COVID-19 treatment. Merck said the royalty-free license would apply to 105 low- and middle-income countries.

Merck Inks Licensing Pact To Broaden Generic Manufacturing Of COVID-19 Antiviral

The agreement, one of the first to share a critical Covid-19 technology, would allow the drug to be made and sold cheaply in 105 low- and middle-income countries.

Merck Inks Deal To Share Antiviral Covid Pill With Poorer Countries

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Presents New Data from Ongoing Phase 2b Trial Evaluating Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 at EACS 2021

Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir to Increase Broad Access in Low- and Middle-Income Countries

The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries

Merck is scheduled to report its Q3 2021 results on Thursday, October 28. We expect the company to likely post revenue and earnings below the consensus estimates, as the spread of Covid-19 delta variant likely impacted the company's overall vaccine sales growth, including that for Gardasil.

What To Expect From Merck's Q3?

FOSTER CITY, Calif. & KENILWORTH, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the start of a Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy. “Partnerships and collaborations are critical to continuing the tremendous progress

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

Pfizer has achieved tremendous success with its COVID-19 vaccine: Comirnaty. It continues to be the leading mRNA vaccine worldwide.

Merck Vs. Pfizer: Which Healthcare Stock Is The Better Buy?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.

Merck (MRK) to Report Q3 Earnings: What's in the Cards?

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Top-Line Results from Phase 3 Trials for Once-Daily Oral Combination of Doravirine/Islatravir for Treatment HIV-1 Infection

Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection

Merck MRK, -0.02% and partner Ridgeback Biotherapeutics said Monday the European Medicines Agency has started a rolling review of molnupiravir, its oral antiviral treatment for COVID-19 in adults. "Merck plans to work with the EMA's Committee for Medicinal Products for Human Use (CHMP) to complete the rolling review process to facilitate initiating the formal review of the Marketing Authorization Application," the company said in a statement.

Merck and Ridgeback Biotherapeutics announce start of rolling review of COVID antiviral in Europe

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Announce Rolling Review by European Medicines Agency for Molnupiravir, an Oral Antiviral Medicine, for the Treatment of COVID-19

Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults

Signs point to yes, but it's still early in the game.

Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?

Great Western Bancorp

HollyFrontier

Meredith

Acceleron Pharma

NEW YORK, Oct. 22, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP305 Broadway, 7th Floor New York, NY  10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Meredith Corporation (NYSE: MDP) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Meredith Corporation (NYSE: MDP) in connection with the proposed acquisition of the company by IAC/InterActiveCorp.  Under the terms of the merger agreement, MDP shareholders will receive $42.18 per share in cash for each share of MDP common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Reminds MDP, GWB, XLRN and HFC Shareholders About Its Ongoing Investigations

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--EC Approves Merck's KEYTRUDA Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic TNBC

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)

Molnupiravir seems likely to shake up the COVID-19 antibody therapy market.

Will Merck's COVID-19 Pill Sink Regeneron's and Eli Lilly's Antibody Therapy Sales?

Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Merck Stock (MRK)